Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 38

recruiting
3 977
countries
28
conditions
2 106

973 trials match your criteria

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Cutaneous lupus erythematosus

Not recruiting

Study on IMVT-1402 for Patients with Active Cutaneous Lupus Erythematosus

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart

Familial hypertriglyceridaemia+1

Not recruiting

Study of ISIS 678354 for Patients with Severe High Triglycerides

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.